Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...
Caffeine could act as an on-off switch for gene and cell therapies, giving doctors more precise control over powerful ...
Chimeric antigen receptor (CAR) T cell therapy leverages patients’ immune systems to fight cancer. This immunotherapy greatly expanded treatment options for cancers like leukemia and lymphoma. However ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results